Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate
Authors:
- 1 January 1989
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 37 (5) , 533-536
Abstract
The pharmacokinetics of bismuth subcitrate were studied in plasma and urine under conditions of single and multiple dosing (28–56 days) using atomic absorption technique. Single dose plasma pharmacokinetics showed peak concentrations of 5.5–57.5 µg·l−1 (mean=24.7 µg·l−1), reached between 30 and 60 min post dosing with an apparent biphasic elimination pattern. Multiple dose studies showed a continuing rise in plasma concentration and urine excretion rate reaching apparent steady-state levels over 7–29 days (mean=18 days). Washout studies in 6 individuals reciprocated accumulation. Maximum equilibrated plasma levels of 7.6–58.3 µg·l−1 (mean=38.3 µg·l−1) were well below those associated with encephalopathy. The half-life of bismuth elimination was 20.7 days. Present patterns of intermittent dosing with bismuth are unlikely to be associated with bismuth accumulation despite slow accumulation and elimination.Keywords
This publication has 19 references indexed in Scilit:
- Relapse Rate as a Major Determinant of Drug Selection in Peptic Ulcer TherapyDrugs, 1988
- Relapse of duodenal ulcer: does it matter which drug is used in initial treatment?BMJ, 1986
- Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.BMJ, 1986
- COMPARISON OF TRI-POTASSIUM DI-CITRATO BISMUTHATE TABLETS WITH RANITIDINE IN HEALING AND RELAPSE OF DUODENAL ULCERSThe Lancet, 1985
- THE CHOICE OF ULCER HEALING AGENT INFLUENCES DUODENAL ULCER RELAPSE RATE AND LONG‐TERM CLINICAL OUTCOMEAustralian and New Zealand Journal of Medicine, 1985
- Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine.1984
- RELAPSE RATES IN DUODENAL ULCER PATIENTS FORMERLY TREATED WITH BISMUTH SUBCITRATE OR MAINTAINED WITH CIMETIDINEThe Lancet, 1984
- DIFFERENCE IN RELAPSE RATES OF DUODENAL ULCER AFTER HEALING WITH CIMETIDINE OR TRIPOTASSIUM DICITRATO BISMUTHATEThe Lancet, 1981
- Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies of 45 patientsJournal of Neurology, Neurosurgery & Psychiatry, 1977
- Encéphalopathies myocloniques iatrogènes aux sels de bismuthJournal of the Neurological Sciences, 1976